- Home
- QURE vs CERT Comparison
QURE vs CERT Comparison
Compare QURE & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | CERT |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QURE | CERT |
|---|---|---|
| Price | $23.37 | $6.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $56.25 | $12.78 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.75 |
| Revenue Next Year | $142.93 | $6.32 |
| P/E Ratio | ★ N/A | $96.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $6.45 |
| 52 Week High | $71.50 | $15.38 |
Technical Indicators
Market Signals| Indicator | QURE | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 19.92 |
| Support Level | $20.17 | $6.45 |
| Resistance Level | $26.97 | $7.29 |
| Average True Range (ATR) | 2.25 | 0.42 |
| MACD | -0.26 | -0.17 |
| Stochastic Oscillator | 38.75 | 3.49 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.